Deadline: 24 May 2024
Applications are now open for the Genewiz Oncology Grants 2024 . Genewiz is proud to recognise excellence in oncology research with tailored funding to support its ongoing discovery. As part of the Oncology Insights Grant programme, four researchers will receive an oncology-focused grant to use in a service with Azenta Life Sciences' GENEWIZ Multiomics & Synthesis Solutions - including gene synthesis, precision antibody discovery using machine learning, next-generation sequencing (NGS) and Olink proteomics.
Grants include:
- A concession to an oncological application of gene synthesis: traditional molecular cloning methods are often complex. Gene synthesis provides an efficient method for rapidly generating constructs for exploring cancer mechanisms in vitro, while also providing precise sequence vectors for therapeutic development. Taking advantage of gene synthesis in your cancer research can allow you to efficiently characterise the effects of genomic mutations on cell function mechanisms.
- A concession to a Precision Antibody Discovery oncology application: selecting the right antibody leads from a large upstream pool with favourable downstream development characteristics the first time is essential for rapid and successful therapeutic development. Combining NGS, machine learning bioinformatics and recombinant antibody production in a single workflow, its Precision Antibody Discovery service allows you to quickly uncover multiple leads that you would otherwise miss with traditional screening technologies and processes - uncovering 5 to 10 times more leads than low-throughput approaches.
- A grant for an oncology NGS application: Cancer researchers can use whole-genome, exome and targeted amplicon next-generation sequencing (NGS) approaches to characterise cancer-associated mutations and other biomarkers. Leveraging the latest long- and short-read technology, GENEWIZ Next-Generation Sequencing can help you gain a broader perspective and understanding of your research with comprehensive genomic coverage.
- A grant for an oncology application of Olink Proteomics: Olink Proteomics enables simultaneous, high-throughput analysis of proteins with high specificity and sensitivity using minimal sample amounts to provide an in-depth understanding of disease and drug response. Using protein biomarker detection with Olink Proteomics, clinical trial researchers can identify known cancer biomarkers in a patient population to accurately identify subsets of the population with greater sensitivity to the therapeutic being tested.
Subsidies
- One prize consists of a value of US$ 5,000 (or the equivalent in local currency) for a single GENEWIZ Gene Synthesis oncology application (with no restrictions on trial type).
- A second prize consists of a credit of US$ 10,000 (or the equivalent in local currency) for a single order using the recently introduced GENEWIZ Precision Antibody Discovery (PAD) service.
- A third prize of US$ 5,000 (or its equivalent in local currency) will be allocated to a single application using GENEWIZ next-generation sequencing in an oncology-related application.
- The fourth and final prize of US$ 5,000 (or the equivalent in local currency) will be used for a single order using the GENEWIZ Olink Proteomics® services offered through GENEWIZ by Azenta Life Sciences. All amounts granted will be made available in the form of an account credit. Any unused credit will be forfeited and cannot be transferred to another project.
Eligibility
- Open to individuals professionally involved in scientific research in the laboratory and who have reached at least the age of majority in their jurisdiction of residence (participants must in any case be at least 18 years old).
- Employees, officers, directors, agents, representatives and independent contractors of the Sponsors, their subsidiaries or affiliated companies, together with their immediate family members and members of the same household (whether related or not) are not eligible to participate.
Application
Applications for the GENEWIZ Oncology Insights Grant Programme will close on 24 May 2024 at 23:59 (ET).
